ASCO Annual Meeting

Giredestrant plus palbociclib improved PFS numerically just shy of 5 months in the persevERA trial, but was deemed negative due to lack of statistical significance.

PSMAddition subgroup data show lutetium PSMA-617 triplet yields consistent rPFS, PSA, and mCRPC benefits regardless of disease volume or mHSPC status.

Sacituzumab govitecan plus pembrolizumab improved PFS2 and delayed subsequent therapy vs chemo/pembrolizumab in PD-L1+ mTNBC.

Pemigatinib improved PFS as first-line therapy for FGFR2-rearranged cholangiocarcinoma in the phase 3 FIGHT-302 trial.

Prespecified biomarker analyses of ASCENT-03 and ASCENT-04 showed longer PFS with sacituzumab govitecan–based regimens vs comparators in TNBC.

Rilvegostomig plus T-DXd yielded high pCR rates in immune-positive HER2-negative breast cancer.

Frontline darovasertib plus crizotinib improved PFS vs investigator’s choice of therapy in patients with HLA-A*02:01–negative metastatic uveal melanoma.

Linda R. Mileshkin, MBBS, FRACP, Mbioeth, highlights efficacy data with puxitatug samrotecan in patients with ovarian and endometrial cancers.

FLAME data show ctDNA-guided addition of chemotherapy to osimertinib improved PFS vs osimertinib alone in EGFR-mutant NSCLC.

Circulating tumor DNA analyses from the phase 1/1b StrateGIST-1 trial also support baseline ctDNA detectability as a potentially prognostic marker in this population.

Ahead of the 2026 ASCO Annual Meeting, results from the final analysis of the phase 3 KEYNOTE-522 study have been released.

STRIDE plus lenvatinib and TACE significantly improved PFS vs TACE alone in patients with unresectable embolization-eligible HCC.

The phase 3 HARMONi-6 showed an overall survival benefit with ivonescimab plus chemotherapy vs tislelizumab plus chemotherapy in squamous NSCLC.

Perioperative apalutamide plus ADT improved metastasis-free survival and pathologic responses in high-risk localized prostate cancer.

Abemaciclib markedly improved PFS vs placebo in patients with advanced dedifferentiated liposarcoma.

Daniel King, MD, PhD, discusses the implications of the RASolute 302 study of daraxonrasib in previously treated metastatic pancreatic adenocarcinoma.

Joyce Nuqui Barlin, MD, shares the rationale for studying gotistobart plus pembrolizumab in patients with pretreated platinum-resistant ovarian cancer.

Analyses from the evERA trial showed PFS2 and chemotherapy-free survival gains with giredestrant plus everolimus in ER+ breast cancer subgroups.

CIRCULATE provides the first prospective randomized evidence in support of a ctDNA-guided treatment escalation strategy in pMMR/MSS stage II colon cancer.

DVRd maintained efficacy benefits over VRd in transplant-ineligible, newly diagnosed multiple myeloma.

Encorafenib plus cetuximab and FOLFIRI improved PFS vs chemotherapy alone in first-line BRAF V600E–mutant metastatic colorectal cancer.

Tafasitamab plus lenalidomide and R-CHOP showed significant PFS improvements compared with R-CHOP alone in diffuse large B-cell lymphoma.

At the 2026 ASCO Annual Meeting, 3.5-year follow-up findings from the phase 3 EV-302/KEYNOTE-A39 study have been presented.

Adjuvant selpercatinib cut recurrence or death risk by 83% vs placebo in stage IB-IIIA RET fusion–positive NSCLC in LIBRETTO-432.

In the phase 3 RASolute 302 trial, daraxonrasib nearly doubled OS vs chemotherapy in previously treated metastatic PDAC, cutting the risk of death by 60%.

Ultra-low-dose nivolumab plus oral metronomic chemotherapy cut the risk of death by 43% versus paclitaxel-carboplatin in first-line platinum-sensitive recurrent or metastatic HNSCC.

Lucy Gilbert, MD, discusses overall survival data with relacorilant plus nab-paclitaxel based on prior taxane use from the phase 3 ROSELLA trial in platinum-resistant ovarian cancer.

Coral Olazagasti, MD, discusses the significance of providing resources to oncology physicians who are looking to strengthen their overall wellness.